François Mongrain
Directeur Général chez Mimetogen Pharmaceuticals, Inc.
Profil
François Mongrain is the founder of Bellus Health (Innodia), Inc. He is currently the Director at Laurent Pharmaceuticals, Inc. and the Chief Executive & Financial Officer at Mimetogen Pharmaceuticals, Inc. Previously, he worked as a Principal at Ernst & Young LLP (Canada).
He completed his undergraduate degree at HEC Montréal.
Postes actifs de François Mongrain
| Sociétés | Poste | Début |
|---|---|---|
Mimetogen Pharmaceuticals, Inc.
 Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada. | Directeur Général | - |
Laurent Pharmaceuticals, Inc.
 Laurent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Laurent Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops clinical stage, orally-active drug candidate with potential to modulate the immuno-inflammatory response in cystic fibrosis patients. The company was founded in 2012 and is headquartered in Montr?al, Canada. | Directeur/Membre du Conseil | - |
Anciens postes connus de François Mongrain
| Sociétés | Poste | Fin |
|---|---|---|
Ernst & Young LLP (Canada)
 Ernst & Young LLP (Canada) Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP (Canada) engages in the provision of consulting, assurance, tax, and transaction services. The company is headquartered in Toronto, Canada. | Corporate Officer/Principal | - |
Bellus Health (Innodia), Inc.
 Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | Fondateur | - |
Formation de François Mongrain
| HEC Montréal | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Bellus Health (Innodia), Inc.
Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | Health Technology |
Ernst & Young LLP (Canada)
Ernst & Young LLP (Canada) Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP (Canada) engages in the provision of consulting, assurance, tax, and transaction services. The company is headquartered in Toronto, Canada. | Commercial Services |
Mimetogen Pharmaceuticals, Inc.
Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada. | Health Technology |
Laurent Pharmaceuticals, Inc.
Laurent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Laurent Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops clinical stage, orally-active drug candidate with potential to modulate the immuno-inflammatory response in cystic fibrosis patients. The company was founded in 2012 and is headquartered in Montr?al, Canada. | Health Technology |